Is the Push for Higher HPV Vaccination Rates Justified?; CBCD Reviews a Report

Share Article

“Federal goal is to vaccinate 80% of boys and girls against HPV by 2020,” according to a report published in the Wall Street Journal on November 10, 2014. (1) The CBCD shares additional information, and recommends Novirin against the Latent HPV.

News Image
I want to see fundamental studies proving efficacy, and they do not exist. - Dr. Uzi Beller (2)

“Infected with the HPV virus? The CBCD recommends taking Novirin or Gene-Eden-VIR.” - Greg Bennett, CBCD

The United States government has embarked on a campaign to increase HPV vaccination rates in both boys and girls, according to an article in the Wall Street Journal. “The National Cancer Institute announced recently it is pouring nearly $2.7 million into 18 U.S. cancer centers to boost HPV vaccinations among boys and girls.” (1) Maura Gillison, a professor in the College of Medicine at Ohio State University Comprehensive Cancer Center, said that now, as cervical-cancer rates are falling and oral-cancer rates in men steadily rise, ‘the burden of HPV cancer is shifting to men.’ (1) The report went on to note that “vaccination rates remain stifled, despite the availability of two vaccines that experts say provide effective coverage against cancer. The Department of Health and Human Services’ goal is to boost HPV-vaccination rates to 80% by 2020 - which is far higher than the 38% of girls and 14% of boys who completed the three-dose HPV vaccine last year, according to data from the National Immunization Survey of teenagers.” (1)
The Center for the Biology of Chronic Disease (CBCD) adds its voice to that of Dr. Uzi Beller, chief professor of obstetrics/gynecology at Shaare Zedek Medical Center in Israel, who urged the medical community to be cautious in regards to HPV vaccination. “I want to see fundamental studies proving efficacy, and they do not exist.” (See the Jerusalem Post, from September 21, 2013) (2) The vaccines, Beller said, “were tested on mostly white women attending colleges and university - mostly from developed countries and healthy. The data were based on a relatively short term follow-up period. What is known does not yet justify widespread vaccination of healthy girls (2).” In addition, Dr. Beller said that “there is no evidence that prophylactic (preventative) vaccination against HPV types 16 and 18 reduces the incidence of cervical cancer.” As the vaccine costs $100 to $360 for three doses in wealthy countries, it is completely out of the reach of developing countries, where an effective vaccine would be most urgently needed (2).”

The Jerusalem Post report concluded that “pediatricians are important advocates for preventive medicine, but they may know little about HPV infection and cervical and other HPV-related cancers. Obstetricians / Gynecologists know about HPV and cervical cancer prevention, but they often know little about vaccines and immunization delivery (2).”

Click to learn more about HPV symptoms.

“We believe doctors need facts. Many times, they’re recommending vaccination to their patients because that’s the shpiel they get from the CDC, the FDA, and The Department of Health and Human Services. We believe many doctors would choose to recommend a more natural approach if they could be sure of that approach’s safety and efficacy. We’re happy to say that a study conducted by the Center for the Biology of Chronic Disease (CBCD) showed exactly that.” – Greg Bennett, CBCD

A recent post marketing clinical study published in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs on August 12, 2013 showed that the formula of Novirin and Gene-Eden-VIR reduced HPV symptoms and was safe and effective (3).

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HPV…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (3) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (3)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Doctors can view the papers on Gene-Eden-VIR here:

Are there other treatments or remedies available against the HPV?

“There are no drugs approved against the HPV. Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus (this is before the HPV has caused cancer). The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission.” (3) In contrast, the formula of Novirin and Gene-Eden-VIR was shown to reduce HPV symptoms in two separate post-marketing clinical studies that followed FDA guidelines.

The CBCD therefore recommends that individuals infected with HPV take Novirin or Gene-Eden-VIR.

Click to read more about Novirin and the HPV, or Gene-Eden-VIR and the HPV.


(1)    McCabe, C. "Federal Goal Is to Vaccinate 80% of Boys and Girls Against HPV by 2020." Published Nov. 10, 2014.

(2)    Siegel-Itzkovich, J. "HPV: To vaccinate or not to vaccinate." Published September 21, 2013.

(3)    Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Greg Bennett
+1 5852509999
Email >
Visit website